d-甘露糖醛酸内酯中的6 R-和6 S -6 C-甲基甘露糖。抑制磷酸葡萄糖变位酶和磷酸甘露糖异位酶:用于研究甘露糖初级代谢的药物
摘要:
6 S - 3和6 R - 6 6 C-甲基甘露糖的合成分别依赖于衍生自d-甘露糖醛酸内酯的完全和部分受保护的酮的相反和高度立体选择性还原。硼氢化钠还原甲硅烷基化的酮2伴随着甲硅烷基保护基团的完全迁移到新的立体异构中心。当在氯化铈(III)存在下进行还原时,甲硅烷基迁移被抑制。两种差向异构体都是磷酸葡萄糖变位酶和磷酸甘露糖突变酶的良好抑制剂,并且是磷酸己糖合酶的特异性抑制剂。这项工作证实了6 C-烷基己糖提供了一组有价值的,具有良好生物利用度的化合物,用于研究与糖磷酸酯的初级代谢有关的酶。-7-脱氧-2,3-的X射线晶体分析:5,6二ö异亚丙基α-L- -glycero- d -manno- heptofuranose 16进行报告。
d-甘露糖醛酸内酯中的6 R-和6 S -6 C-甲基甘露糖。抑制磷酸葡萄糖变位酶和磷酸甘露糖异位酶:用于研究甘露糖初级代谢的药物
摘要:
6 S - 3和6 R - 6 6 C-甲基甘露糖的合成分别依赖于衍生自d-甘露糖醛酸内酯的完全和部分受保护的酮的相反和高度立体选择性还原。硼氢化钠还原甲硅烷基化的酮2伴随着甲硅烷基保护基团的完全迁移到新的立体异构中心。当在氯化铈(III)存在下进行还原时,甲硅烷基迁移被抑制。两种差向异构体都是磷酸葡萄糖变位酶和磷酸甘露糖突变酶的良好抑制剂,并且是磷酸己糖合酶的特异性抑制剂。这项工作证实了6 C-烷基己糖提供了一组有价值的,具有良好生物利用度的化合物,用于研究与糖磷酸酯的初级代谢有关的酶。-7-脱氧-2,3-的X射线晶体分析:5,6二ö异亚丙基α-L- -glycero- d -manno- heptofuranose 16进行报告。
Chemoenzymatic synthesis of the epimeric 6C-methyl-D-mannoses from toluene
作者:Martin G. Banwell、Andrew M. Bray、Alison J. Edwards、David J. Wong
DOI:10.1039/b005312k
日期:——
The title compounds 1 and 2, which are effective and specific inhibitors of phosphohexomutases, have been prepared in enantiomerically pure form from toluene. The initial step of the reaction sequence involves enzymatic cis-1,2-dihydroxylation of toluene by E. coli JM109 (pDTG601) to give the cis-1,2-dihydrocatechol 3. The latter compound is then converted, ia a series of chemical oxidation and reduction steps, into compounds 1 and 2. The X-ray crystal structures of the bis-acetonide derivatives 11, 13 and 14 have been determined.
MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS
申请人:Vertex Pharmaceuticals Incorporated
公开号:EP2970353B1
公开(公告)日:2018-04-18
US20140274930A1
申请人:——
公开号:US20140274930A1
公开(公告)日:2014-09-18
US9890176B2
申请人:——
公开号:US9890176B2
公开(公告)日:2018-02-13
[EN] MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS<br/>[FR] DÉRIVÉS DU MANNOSE POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES
申请人:VERTEX PHARMA
公开号:WO2014165107A2
公开(公告)日:2014-10-09
The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula (I) The invention also provides processes for making the compounds described herein. Furthermore, the present invention provides a composition comprising the compounds described herein, and a pharmaceutically acceptable carrier, adjuvant, or vehicle. The present invention also provides methods of treating or preventing bacteria infection in a subject, comprising administering to the subject an effective amount of the compound or the composition described herein.